Wnt Signaling Pathway in Oncology Drug Pipeline Update
|出版商||BioSeeker Group AB||商品編碼||171794|
Abnormalities in the Wnt signaling pathway are associated with a large variety of human malignancies including tumors of breast, colon, pancreas, liver and bone.
There are today 228 companies plus partners developing 253 Wnt pathway targeting drugs in 935 developmental projects in cancer. In addition, there are 2 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 118 drugs. Wnt Signaling Pathway In Oncology Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to 204 different targets. All included targets have been cross-referenced for the presence of mutations associated with human cancer. To date 199 out of the 200 studied drug targets so far have been recorded with somatic mutations. The software application lets you narrow in on these mutations and links out to the mutational analysis for each of the drug targets for detailed information. All drugs targets are further categorized on in the software application by 42 classifications of molecular function and with pathway referrals to BioCarta, KEGG, NCI-Nature and NetPath.
Drug name & Synonyms
Target Expression Profile
Principal Company & Partners
Target and Molecular Function of Target
Fillings and Approvals
Phase IV Data
Phase III Data
Phase II Data
Phase I Data
Phase 0 Data
Dynamic Report Generator